List of Excipients in Branded Drug ASTAGRAF XL

« Back to Dashboard

Last updated: August 14, 2026

ecutive summary: Astagraf XL is a once-daily extended-release tacrolimus capsule whose commercial value depends on controlled drug release, dose proportionality, low batch-to-batch variability, and reliable therapeutic-drug monitoring. The excipient opportunity is not a simple substitution exercise. Tacrolimus is a narrow-therapeutic-index drug, and changes to polymers, diluents, lubricants, capsule shells, or coating systems can alter dissolution and exposure. The most attractive opportunities are generic or differentiated extended-release products, excipient supplier partnerships, regional manufacturing, and formulation platforms that reduce variability without changing the tacrolimus dose.

Astagraf XL Excipient Strategy, Patent Position, and Commercial Opportunities

What is Astagraf XL and how does its formulation work?

Astagraf XL is an extended-release oral capsule containing tacrolimus, an immunosuppressant used for prophylaxis of organ rejection in adult kidney transplant recipients. It is marketed by Astellas Pharma US and is administered once daily, unlike immediate-release tacrolimus products that are generally administered twice daily.[1]

The formulation uses a modified-release matrix or coating approach to control tacrolimus release through the gastrointestinal tract. The commercial formulation contains tacrolimus with inactive ingredients that include release-controlling polymers, lactose, magnesium stearate, and capsule-shell components. The exact excipient profile varies by capsule strength and color.[1]

Product attribute	Astagraf XL
Active ingredient	Tacrolimus
Dosage form	Extended-release hard capsule
Strengths	0.5 mg, 1 mg, 5 mg
Administration	Once daily
Primary U.S. indication	Kidney-transplant rejection prophylaxis
FDA approval	July 2013
Regulatory pathway	New drug application
Therapeutic class	Calcineurin inhibitor
Generic classification issue	Modified-release, narrow-therapeutic-index product
Biosimilar relevance	None; tacrolimus is a small molecule

Astagraf XL is not interchangeable with immediate-release tacrolimus or with other extended-release tacrolimus products without prescriber supervision. The FDA label requires dose adjustment based on tacrolimus whole-blood trough concentrations and clinical response.[1]

Which excipients are used in Astagraf XL?

The main excipient functions are release control, powder processing, capsule manufacture, and product identification.

Excipient category	Likely functional role in the product
Hypromellose	Hydrophilic release-controlling polymer and matrix former
Ethylcellulose	Water-insoluble release barrier or diffusion-control polymer
Lactose monohydrate	Diluent and carrier
Magnesium stearate	Lubricant for powder processing and capsule filling
Gelatin	Hard-capsule shell
Titanium dioxide and iron oxides	Opacification and strength-specific coloration

The commercial formulation strategy balances several competing requirements:

1. Tacrolimus must be released slowly enough to support once-daily administration.
2. Release must remain consistent across pH conditions and gastrointestinal transit.
3. The formulation must deliver predictable exposure despite tacrolimus’s low dose and high potency.
4. The powder blend must have adequate flow and content uniformity.
5. The capsule must remain stable through long-term storage and distribution.

Excipient selection is constrained by tacrolimus’s physicochemical properties. The drug is practically insoluble in water, has low dose loading, and is highly sensitive to formulation and absorption conditions. Small changes in particle size, wetting, polymer grade, lubricant concentration, or coating structure can affect dissolution and systemic exposure.

What is the best excipient strategy for a generic Astagraf XL product?

The strongest strategy is a controlled Q1/Q2 formulation that uses well-characterized excipients with established regulatory histories while reproducing the reference product’s critical release behavior.

Use polymer combinations rather than a single release-control material

A hydrophilic polymer such as hypromellose can provide swelling and gel formation. Ethylcellulose can reduce water penetration and slow diffusion. A combination gives the developer more control over:

• Initial drug release
• Midpoint dissolution
• Late-stage release
• Sensitivity to agitation
• Sensitivity to gastrointestinal pH
• Capsule-to-capsule variability

A single-polymer approach may reduce manufacturing complexity, but it can make the product more sensitive to polymer viscosity, particle size, compression or filling density, and manufacturing scale.

Control polymer grade tightly

For hypromellose, substitution type, viscosity grade, particle size, and hydration behavior can materially affect release. For ethylcellulose, polymer particle size, ethoxyl content, viscosity, and dispersion quality influence permeability and film formation.

A commercial excipient strategy should qualify at least two sources where possible, but dual sourcing must not create a clinically meaningful dissolution shift. Supplier changes should be managed through comparability protocols covering:

• Assay and content uniformity
• Multiparticulate or blend distribution
• Disintegration
• Dissolution across multiple pH media
• Accelerated and long-term stability
• Tacrolimus degradation products
• In vivo exposure, where required

Minimize lubricant-driven variability

Magnesium stearate improves capsule-filling performance but can reduce wetting and delay dissolution if overmixed or over-lubricated. The commercial target should be the lowest concentration that supports reliable manufacturing.

Lubrication time, mixing energy, and order of addition are process variables. A generic developer that treats magnesium stearate as a routine excipient may create unacceptable lot-to-lot differences.

Preserve low-dose content uniformity

The 0.5 mg capsule presents the greatest content-uniformity challenge. At low drug loading, geometric dilution, pre-blending, ordered mixing, and segregation control become central to commercial viability.

The formulation should be evaluated for:

• Blend segregation during transfer
• Hopper residence time
• Capsule-fill weight variation
• Drug distribution within the blend
• Sampling bias
• Losses during line clearance
• Electrostatic interactions with equipment

A supplier that can provide engineered tacrolimus premixes or high-uniformity intermediate blends may capture value beyond commodity excipient supply.

What formulation patents protect Astagraf XL?

The relevant intellectual-property protection is directed primarily to the extended-release dosage form, tacrolimus release profile, manufacturing process, and therapeutic use. Individual excipients such as hypromellose, lactose, ethylcellulose, and magnesium stearate are generally established pharmaceutical materials and are not, by themselves, the commercial barrier.

Potential claim categories include:

Claim category	Commercial relevance
Extended-release tacrolimus composition	May cover polymer ratios, release profile, or dosage-form architecture
Once-daily tacrolimus treatment	May cover dosing methods in transplant patients
Dissolution or pharmacokinetic profile	Can create development barriers if narrowly claimed
Capsule manufacturing process	May constrain blending, coating, filling, or scale-up
Specific excipient combinations	May affect design-around options
Stability or impurity-control process	Can protect manufacturing know-how rather than the basic product

The FDA Orange Book is the controlling source for currently listed U.S. patents and regulatory exclusivities associated with Astagraf XL.[2] Patent term must be assessed separately from approval exclusivity because formulation patents, method-of-use patents, terminal disclaimers, patent-term adjustment, and patent-term extension can produce different end dates.

A competitor should not assume that an excipient change avoids infringement. A patent claim may cover a release profile, a polymer combination, a dissolution result, or a functional limitation rather than a named excipient alone.

When did Astagraf XL lose regulatory exclusivity?

Astagraf XL’s principal regulatory barrier was not biologic exclusivity or a long new-chemical-entity period. Tacrolimus was already an approved active ingredient before Astagraf XL. The product’s regulatory protection therefore centered on the new extended-release dosage form, clinical data, and any listed patents.

The main regulatory milestones are:

Date	Event
1994	Tacrolimus approved in the United States as an immediate-release product
July 2013	Astagraf XL approved by FDA
2013 onward	Once-daily extended-release tacrolimus commercialized for kidney transplantation
Post-approval period	Product-specific safety, labeling, manufacturing, and patent barriers continued to affect generic entry

A new dosage form can receive approval-related exclusivity for clinical investigations even when the active ingredient is old. That exclusivity is shorter than the five-year NCE period and does not prevent all forms of competing development. Patent status and the practical complexity of demonstrating bioequivalence have been more important than the original approval date.

What is the Orange Book status of Astagraf XL?

Astagraf XL is an FDA-approved small-molecule prescription drug subject to Orange Book analysis, not a biologic reference product under the biosimilar pathway.[2]

For a generic developer, the relevant pathway is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must address:

• Listed patents and certifications
• Product-specific bioequivalence requirements
• Extended-release dissolution
• Tacrolimus therapeutic-index considerations
• Strength-specific content uniformity
• Labeling differences
• Manufacturing and stability requirements

The critical regulatory issue is substitution. An extended-release tacrolimus capsule cannot be treated as interchangeable merely because it contains the same active ingredient. The dosage form, release rate, exposure profile, and label must satisfy FDA requirements.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV strategy could challenge listed patents while the generic applicant develops an ANDA. The key risks are:

1. A patent claim covering the release-control architecture.
2. A method-of-use claim covering once-daily tacrolimus administration.
3. A patent covering a dissolution or pharmacokinetic profile.
4. A patent covering manufacturing conditions that are difficult to design around.
5. A 30-month stay following timely patent litigation after a Paragraph IV notice.

The litigation value of Astagraf XL is likely lower than that of a major mass-market product because tacrolimus competition already includes immediate-release generics and another extended-release product, Envarsus XR. The commercial stakes remain meaningful because transplant patients require chronic treatment, switching can create clinical risk, and tacrolimus monitoring generates operational costs.

No biosimilar litigation pathway applies. A competing tacrolimus product would be a generic or alternative new drug application, not a biosimilar.

How does Astagraf XL compare with Envarsus XR and immediate-release tacrolimus?

Product	Release profile	Dosing pattern	Competitive position
Prograf and generic tacrolimus	Immediate release	Usually twice daily	Lowest-cost and most established generic segment
Astagraf XL	Extended release	Once daily	Adherence and regimen simplification
Envarsus XR	Extended release with distinct delivery technology	Once daily	Differentiated exposure and reduced-dose positioning in some patients

Astagraf XL competes with Envarsus XR on adherence, pharmacokinetics, physician familiarity, payer access, and switching complexity. It competes with immediate-release tacrolimus on price and convenience.

The excipient opportunity is therefore not limited to copying Astagraf XL. A developer can pursue:

• A direct generic equivalent
• A distinct extended-release tacrolimus product
• A lower-variability formulation
• A formulation optimized for regional excipient availability
• A capsule platform that supports multiple release rates
• A transplant-focused product with monitoring and adherence services

A direct generic has the clearest regulatory path but faces the greatest substitutability and price pressure. A differentiated formulation may support stronger pricing but requires more clinical and regulatory investment.

What commercial opportunities exist in Astagraf XL excipients?

Generic extended-release development

The most immediate opportunity is a generic tacrolimus extended-release capsule. The product has chronic use, an established active ingredient, and a defined clinical market. The main barriers are bioequivalence, narrow-therapeutic-index risk, and formulation reproducibility.

A successful product must match the reference product across multiple dissolution conditions and demonstrate acceptable pharmacokinetic exposure. A formulation that passes a single dissolution condition but fails under agitation or pH variation is commercially weak.

Specialty excipient supply

Excipient suppliers can compete through technical support rather than price alone. Valuable offerings include:

• Consistent hypromellose grades
• Controlled-particle-size ethylcellulose
• Low-moisture lactose
• Directly compressible or capsule-fillable diluents
• Low-peroxide excipient grades
• Regulatory support packages
• Dual-source qualification
• Process-development assistance

Because tacrolimus is potent and the dose is low, suppliers that provide reproducible excipient functionality can reduce development risk.

Co-development and licensing

Licensing opportunities may arise around:

• Polymer-based extended-release platforms
• Multiparticulate systems
• Amorphous or stabilized tacrolimus dispersions
• Capsule-in-capsule technologies
• Modified-release systems that reduce food effect
• Manufacturing processes that improve blend uniformity

A platform owner can license technology to regional generic companies that have manufacturing capacity but lack modified-release expertise.

Regional manufacturing

Astagraf XL-type products are suitable for regional production where transplant programs are expanding and access to imported innovator products is limited. Local commercial value depends on:

• Availability of tacrolimus API
• Reliable controlled-release excipients
• Local bioequivalence capacity
• Pharmacovigilance infrastructure
• Hospital procurement systems
• National substitution rules

The greatest manufacturing barrier is not capsule filling. It is reproducible release and exposure at commercial scale.

Adherence and therapeutic-drug-monitoring services

Once-daily dosing can support adherence programs, but transplant patients still require trough-level monitoring. A commercial product bundled with reminders, refill coordination, laboratory scheduling, and pharmacist support may create differentiation in markets where price competition is intense.

What manufacturing and IP barriers affect generic launch?

The primary barriers are technical rather than raw-material scarcity.

Barrier	Effect on launch
Low-dose drug loading	Raises content-uniformity risk
Poor tacrolimus solubility	Complicates release and absorption control
Polymer variability	Changes dissolution and exposure
Narrow therapeutic index	Raises clinical and regulatory scrutiny
Food and gastrointestinal effects	Can alter tacrolimus exposure
Scale-up of blending	Creates segregation and fill-weight risk
Patent claims	May delay launch or require design-around
Limited transplant substitution	Restricts automatic switching
Pharmacovigilance requirements	Increases post-launch operating cost

Manufacturers should establish a design space around polymer viscosity, particle size, lubricant level, blend time, capsule-fill weight, and dissolution. Process analytical technology can help monitor blend uniformity and capsule weight, but it does not replace clinical bioequivalence evidence.

What is the revenue exposure for Astellas?

Astellas reports transplant products within broader commercial portfolios, but Astagraf XL revenue is not generally disclosed as a standalone line item in public financial reporting. The product’s revenue exposure is therefore best assessed through market share, prescription volume, payer coverage, and the broader tacrolimus franchise rather than a separately reported Astagraf XL figure.[3]

The commercial risk to Astellas comes from:

• Generic extended-release entry
• Price erosion
• Conversion to Envarsus XR
• Hospital formulary decisions
• Reduced use of branded tacrolimus
• Prescriber reluctance to maintain multiple tacrolimus formulations

The revenue opportunity for a competitor is strongest where once-daily dosing is valued but the branded product remains expensive or difficult to procure.

How strong is the Astagraf XL patent estate?

The patent estate is strategically meaningful but technically designable if protection is narrow. Strength depends on whether claims cover:

• The core polymer matrix
• A broad range of excipient ratios
• A measurable dissolution profile
• Pharmacokinetic parameters
• Manufacturing steps
• Methods of treating transplant recipients

A narrow composition claim may be avoided through a different polymer architecture. A broad functional claim tied to release or exposure can be more difficult to design around because a successful generic must still reproduce the reference product’s performance.

Commercial patent strength should be scored against five factors:

Factor	Assessment
Composition breadth	Determines the number of viable formulation designs
Claim overlap with bioequivalent products	Determines design-around difficulty
Remaining patent term	Determines launch timing
Litigation history	Indicates enforceability and settlement risk
Regulatory exclusivity	Determines whether patent challenges are immediately actionable

What generic launch scenarios exist for Astagraf XL?

Scenario 1: Direct ANDA launch

A generic applicant matches the reference formulation closely, certifies against listed patents, and launches after patent resolution or expiry. This is the highest-volume opportunity and the most exposed to price erosion.

Scenario 2: Paragraph IV launch

The applicant challenges listed patents and seeks an early launch after litigation, settlement, or favorable judgment. The upside is greater, but litigation costs and a potential 30-month stay increase risk.

Scenario 3: Alternative extended-release product

A developer uses a different release technology and pursues a separate approval strategy. This may avoid composition claims but generally requires more clinical and regulatory work.

Scenario 4: Regional or tender-driven launch

A manufacturer targets countries where registration standards, substitution rules, or procurement structures allow faster entry. This approach can generate volume without directly competing for U.S. pharmacy substitution.

Key Takeaways

• Astagraf XL is a once-daily extended-release tacrolimus capsule approved for kidney-transplant rejection prophylaxis.
• Its excipient strategy relies on controlled release, low-dose content uniformity, powder-processability, and capsule stability.
• Hypromellose, ethylcellulose, lactose, magnesium stearate, gelatin, titanium dioxide, and iron oxides have distinct formulation roles.
• The main commercial barriers are bioequivalence, narrow-therapeutic-index requirements, dissolution reproducibility, and patent claims.
• Tacrolimus is a small molecule, so biosimilar risk does not apply.
• The strongest opportunities are direct generic development, specialty release-control excipients, technology licensing, regional manufacturing, and adherence-support services.
• Astagraf XL competes with generic immediate-release tacrolimus and Envarsus XR.
• A standalone Astagraf XL revenue figure is not generally disclosed by Astellas.
• The FDA Orange Book and current patent records control the launch analysis for any U.S. generic applicant.

FAQs about Astagraf XL excipients and market entry

Can lactose be replaced in an Astagraf XL generic?

Yes, but the replacement must preserve blend uniformity, capsule filling, stability, dissolution, and bioequivalence. A lactose-free formulation may have commercial value for specific patient or regional markets, but the change can require substantial formulation and regulatory work.

Is Astagraf XL interchangeable with Envarsus XR?

No. Both are extended-release tacrolimus products, but they use different formulation technologies and are not automatically interchangeable without appropriate clinical supervision.

Does Astagraf XL require therapeutic-drug monitoring?

Yes. Tacrolimus exposure varies between patients and can change with interacting medicines, food, organ function, and formulation switches. Whole-blood trough monitoring is central to dosing under the FDA label.[1]

Can an excipient supplier patent a new tacrolimus formulation?

Yes. Patentable subject matter may include a novel composition, polymer combination, release profile, manufacturing process, stabilization method, or dosage regimen. The patent must meet novelty, non-obviousness, enablement, and other applicable requirements.

What is the largest technical risk in commercializing a tacrolimus extended-release capsule?

The largest risk is failure to reproduce the reference product’s exposure and dissolution behavior consistently at commercial scale. Low-dose content uniformity and polymer-driven release variability are central causes of development failure.

References

1. U.S. Food and Drug Administration. (2024). Astagraf XL (tacrolimus extended-release capsules) prescribing information. Astellas Pharma US, Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Astellas Pharma Inc. (2024). Annual report and financial results. Tokyo, Japan: Astellas Pharma Inc.

4. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development: Tacrolimus extended-release capsules. Center for Drug Evaluation and Research.

5. U.S. Pharmacopeia. (2024). General chapter <711> dissolution. In United States Pharmacopeia and National Formulary. Rockville, MD: U.S. Pharmacopeial Convention.